CBD: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=CBD (Cannabidiol) |FDA_approval=Yes, for specific epilepsy syndromes; not FDA-approved for cancer treatment |used_for=Investigational use in cancer treatment, including symptom management and potential anti-tumor effects |clinical_trial_phase=Preclinical studies and early human trials for cancer |common_side_effects=Tiredness, diarrhea, changes in appetite/weight; generally well-tolerated at doses used for epilepsy |OS_with=Not applicable; ongo...") |
No edit summary |
||
| Line 11: | Line 11: | ||
|category=Over-the-Counter Drugs and Supplements | |category=Over-the-Counter Drugs and Supplements | ||
|links= | |links= | ||
|toxicity_level=2 | |||
|toxicity_explanation=The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen. | |||
}} | }} | ||
Revision as of 09:54, 27 March 2024
| Property | Information |
|---|---|
| Drug Name | CBD (Cannabidiol) |
| FDA Approval | Yes, for specific epilepsy syndromes; not FDA-approved for cancer treatment |
| Used for | Investigational use in cancer treatment, including symptom management and potential anti-tumor effects |
| Clinical Trial Phase | Preclinical studies and early human trials for cancer |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Tiredness, diarrhea, changes in appetite/weight; generally well-tolerated at doses used for epilepsy |
| OS without | Not specified |
| OS with | Not applicable; ongoing research into potential impacts on overall survival in cancer patients |
| PFS without | Not specified |
| PFS with | Not applicable; ongoing research into potential impacts on progression-free survival in cancer patients |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2 |
| Toxicity Explanation | The toxicity level of CBD (Cannabidiol) is relatively low. It's been reported to be generally well-tolerated, especially at doses used for epilepsy. Typically, side effects may include tiredness, diarrhea, and changes in appetite or weight. However, as it is currently under investigational use in cancer treatment, including glioblastoma, the potential toxicities specific to cancer patients, particularly those with glioblastoma, are not fully understood and are currently under active research. It's essential to discuss with your healthcare provider before starting any new treatment regimen. |
Notes: CBD, a non-psychoactive component of cannabis, has been explored for its potential therapeutic effects in cancer treatment, including anti-inflammatory, analgesic, and anti-nausea properties, as well as possible direct anti-tumor effects. While preclinical studies have shown promising results, including inhibition of tumor growth and synergistic effects with chemotherapy in models of glioblastoma and other cancers, conclusive evidence from clinical trials is needed to fully understand its efficacy and optimal use in cancer treatment.
From Ben Williams Book: Not specified
Loading comments...
